Table 2.
Comparison of ST-segment elevation myocardial infarction (STEMI) admissions: 2020 study cohort versus 2019 control cohort: procedural characteristics and clinical endpoints
| 2020 study cohort | 2019 control cohort | P value | OR (95% CI) | |
| (n=348) | (n=440) | |||
| Procedural characteristics | ||||
| Lesions treated | 1 (1–1) | 1 (1–1) | 0.15 | |
| Vessels treated | 1 (1–1) | 1 (1–1) | 0.81 | |
| Stents | 1 (1–2) | 1 (1–2) | 0.57 | |
| Total length of stent (mm) | 30 (21–38) | 28 (20–38) | 0.38 | |
| Widest balloon (mm) | 3.5 (3–4) | 3.5 (3–4) | 0.56 | |
| Cardiogenic shock | 47 (13.5%) | 55 (12.5%) | 0.68 | 1.09 (0.72 to 1.64) |
| Gp2b3a inhibitor use | 142 (41%) | 159 (36%) | 0.16 | 1.23 (0.92 to 1.63) |
| Thrombus aspiration use | 68 (19.5%) | 92 (20.9%) | 0.64 | 0.91 (0.65 to 1.30) |
| TIMI flow <3 at end of case | 33 (9.5%) | 31 (7.1%) | 0.21 | 1.32 (0.82 to 2.34) |
| Clinical endpoints | ||||
| ICU admission | 37 (10.6%) | 43 (9.8%) | 0.69 | 1.10 (0.69 to 1.73) |
| Length of stay (days) | 3 (2–4) | 3 (2–5) | <0.001* | |
| In-hospital mortality | 38 (10.9%) | 8.6% (38) | 0.28 | 1.30 (0.81 to 2.08) |
Procedural characteristics and clinical endpoints of patients with STEMI admitted during the study periods in 2020 versus 2019.
*Denotes statistical significance (p<0.05).
ICU, intensive care unit; TIMI, thrombolysis in myocardial infarction.